Marshall Edwards Accelerates Study Timeline and Experiences Cost Reduction through Perceptive Alliance with AG Mednet
BOSTON, Feb. 4 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry’s leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation , today announced it has established an alliance with AG Mednet, a global diagnostic imaging network, to bring greater efficiency to the electronic transport of medical images and a higher level of quality to imaging data. Medical imaging data collected globally from clinical sites will be delivered to Perceptive Informatics through AG Mednet’s secure, web-enabled network.
Through a more efficient image acquisition and collection process, which eliminates medical image file shipments, Perceptive’s alliance with AG Mednet is focused on helping sponsors to realize cost savings. Due to the high image quality available through AG Mednet’s digital delivery system, Perceptive is able to help sponsors decrease the time required for image reviews since less time will be spent on queries and data reconciliation with sites.
“As sponsors increasingly rely on medical imaging to assess new compounds, accelerate development, and decrease the cost of getting treatments to market, we are focused on enhancing the speed of medical image delivery and the quality of associated data,” said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics. “Perceptive’s alliance with AG Mednet is representative of our goal to help clients raise the productivity of the clinical development process to a new level through our eClinical platform.”
Abraham Gutman, President and Chief Executive Officer of AG Mednet, added, “We are pleased to combine the routing power of the AG Mednet network with the leading medical imaging capabilities of Perceptive Informatics to help streamline medical image collection and review for each trial, and together provide tangible benefits to sponsors.”
“Marshall Edwards Inc. is currently working with Perceptive Informatics and AG Mednet on a medical imaging-based study with a focus on increasing efficiencies and reducing costs. We are pleased with the accelerated timeline possible for this study brought by the value of this alliance, as well as many other benefits such as initial cost reductions for courier services related to image delivery,” said Patti Rossi, Pharm. D., Vice President of Clinical Operations, Marshall Edwards, Inc., a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics and subsidiary of Novogen.
AG Mednet, which provides the largest HIPAA and 21 CFR Part 11 compliant image transport and exchange network, routes a broad range of medical imaging modalities, including CT, MRI, ultrasound, PET and digital x-ray. The dedicated, carrier-class network has a robust fiber-optic infrastructure to handle uncompressed files of any type for any size study. The automated system, which enables the secure, seamless electronic transfer of study data from sites to Perceptive’s central image repository, enhances site compliance while providing detailed reporting for regulatory requirements.
AG Mednet, Inc. is a global diagnostic imaging network. Pharmaceutical, biotech and medical device companies, core labs and clinical research organizations utilizing imaging technology as part of their trial protocol rely on AG Mednet’s automated system to enable the secure electronic transfer of cases from hundreds of locations, enhancing site compliance while providing detailed reporting necessary to meet the most stringent regulatory requirements. Additional information about AG Mednet is available at www.agmednet.com.
Perceptive Informatics’ Medical Imaging Group offers a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology imaging. More information about the Medical Imaging capabilities provided by Perceptive Informatics is available at www.perceptive.com
About Perceptive Informatics
Perceptive Informatics, a subsidiary of PAREXEL, is the industry’s leading eClinical solutions provider. Perceptive Informatics offers unprecedented access to innovative eClinical technologies and resources, providing clinical trial sponsors, CROs, and other service providers with the benefits of an extensive line of products and services throughout the entire clinical development lifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers best-in-class eClinical software and services that increase the efficiency and productivity of clinical research. Perceptive’s expansive product portfolio includes Interactive Voice and Web Response Systems (IVRS/IWRS,) Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Rebecca
Passo of SHIFT Communications for PAREXEL International, +1-617-779-1817,
rpasso@shiftcomm.com
Web site: http://www.parexel.com//
